



Poster Session 1: Thursday, February 24: 3:00 pm – 3:30 pm MT

Abstract	Screen	Order	Abstract Title	Presenter
130	1	1	Total Number of Lymph Nodes in Neck Dissection and Its Relation to Cancer-Positive Lymph Nodes as a Prognostic Indicator in Aerodigestive Tract Cancers	Rolina Al-Wassia
131	1	2	The impact of head and neck multidisciplinary clinic on treatment package time during the COVID-19 pandemic: a single institutional experience	Christopher Wilke
132	1	3	Prognostic Significance of Referral Patterns and Time Trends in Head and Neck Cancer Management	Divya Balchander
100	2	1	Institutional comparison between radiation with concurrent cisplatin versus carboplatin/paclitaxel for squamous cell carcinoma of the head and neck (SCCHN)	Marin Abousaud
102	2	2	A Prospective Study of Mucosal Sparing Proton Beam Therapy in Resected Oropharyngeal Cancer Patients	Samir Patel
104	3	1	Management of Positive Main Specimen Margin in Oral Tongue Cancer	Ryan Judd
105	3	2	Adjuvant oropharynx cancer management in the era of TORS and HPV: a recursive partitioning analysis	James Janopaul-Naylor
107	3	3	Does Operability Status Influence Outcomes in Patients with T4 Larynx Cancer Undergoing Larynx Preservation?	Ashley Schlafstein
108	4	1	Predictors of Occult Nodal Involvement in Clinically Node Negative Primary Parotid Carcinoma: An NCDB Analysis	Joshua Lorenz
109	4	2	Elective Neck Treatment for Clinically Node-Negative Salivary Gland Cancer: Observation, Neck Dissection, or Neck Irradiation?	Shauna Campbell
110	4	3	Predictive Molecular Biomarkers for HPV-associated Head and Neck Squamous Cell Carcinoma	Wendell Yarbrough
111	5	1	Have We Made Progress In Early Stage Vocal Cord Cancer With Impaired Cord Mobility?	Alexandra De Leo
112	5	2	The Number of Radiographically Positive Lymph Nodes is Predictive of Survival in HPV-Associated Oropharyngeal Cancer and Further Stratifies Outcomes Beyond Clinical Staging Alone	Adam Sauer
113	5	3	Utility of Intermediate Risk Volumes in Human Papilloma Associated Oropharyngeal Cancer: A Pattern of Failure Analysis	George Yang
114	6	1	Evaluation of Cell-Free HPV DNA in Patients with HPV-Associated Oropharyngeal Cancer Treated with Induction Chemotherapy and Response-Adaptive Therapy	Ari Rosenberg
115	6	2	Acute Toxicity Profile and Early Efficacy Results of De-Escalated, Risk-Directed Post-Operative Adjuvant Therapy for Human Papillomavirus-Positive Oropharynx Squamous-Cell Carcinoma: A Phase 2 Trial	Douglas Adkins
116	6	3	TrilynX: A phase 3 trial of xevinapant and concurrent chemoradiotherapy (CRT) for locally advanced head and neck cancer.	Jonathan Schoenfeld
117	7	1	EVOLVE: Evaluating the Safety of De-escalated Head and Neck Irradiation in HPV Positive Oropharynx Cancer in Non/Minimal Smokers.	Miran Blanchard
118	7	2	Brain Global Structural and Network Topological Alterations in Long-term Nasopharyngeal Cancer Survivors	Rahul Paul
120	7	3	Outcomes of Patients with Adenosquamous Carcinoma of the Head and Neck after Definitive Treatment	David Buchberger
121	8	1	Factors Predictive of Primary Therapeutic Modality in Early-Stage Oropharyngeal Squamous Cell Carcinoma	James Bates
123	8	2	DEHART: Dose-Escalated Hypofractionated Adaptive Radiation Therapy with Atezolizumab for Head and Neck Cancers	Musaddiq Awan
124	8	3	Locoregional Recurrence Trends in Head and Neck Cutaneous Squamous Cell Carcinoma	Alexander Jones

MULTIDISCIPLINARY
HEAD and NECK CANCERS
 SYMPOSIUM



EXTRAORDINARY CARE:
 Collaborative, Targeted, Diverse, Patient Centered

JW Marriott Phoenix Desert Ridge Resort and Spa
 Phoenix, Arizona, February 24-26, 2022
www.headandnecksymposium.org • #HNCS22

Abstract	Screen	Order	Abstract Title	Presenter
125	9	1	Dosimetric Comparison of Intensity Modulated Radiotherapy (IMRT) and Intensity Modulated Proton Therapy (IMPT) for Novel Oral Tongue Avoidance Concept in Low-Risk Squamous Cell Carcinoma of the Oral Tongue	Robert Press
127	9	2	Neoadjuvant QUAD Shot as Temporizing Measure Prior to Definitive Surgery for Locally Advanced Oral Cavity Cancer	My-Lien Truong
129	9	3	Induction chemotherapy with Cisplatin, Paclitaxel, and Capecitabine (PTC) in locally advanced (LA) squamous cell carcinoma of head and neck (SCCHN)	Juan Alvarado-Muñoz
119	10	1	Association of Body Mass Index with Survival Outcome in Patients with Head and Neck Cancer Treated with Combined Modality Therapy	Sung Jun Ma
106	10	2	Optimal Threshold of Neutrophil-Lymphocyte Ratio and Its Association With Survival Outcome Among Patients With Head and Neck Cancer in the United States	Sung Jun Ma
122	10	3	Optimal Threshold of Pre-treatment Hemoglobin Level as a Prognostic Biomarker for Survival Outcome in Patients With Head and Neck Cancer in the Era of Human Papillomavirus	Sung Jun Ma